Cardin, Of the ones you mention, Onyx is the only name I have looked at in detail. I kind of like it, but it didn't make my list of the ones I own. The names I like now, in no particular order, are:
Genzyme Transgenics-gztc, Genzyme Tissue Repair-genzl, Ligand-lgnd, Medarex-medx, Cell Genysis-cege, Chiron-Chir, Myriad-mygn, Shaman-shmn and, as a catch-all for the industry and to participate in some unlisted ventures, H&Q Health Sciences Investment Fund-HQH, currently selling at a dandy 17.4% discount to its net asset value.
My biotech list is smaller than usual because I have sold my gene mapping cos. with the announcement of the Perkin-Elmer machine. Also, though I like the cos. prospects and think the price of the stocks is low, I don't like the overall market and do not believe that these stocks will go up if there is a crash. They will be the first to recover if the science remains excellent, but they are not bullet-proof.
MB |
